Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02566057 · ClinicalTrials.gov registry record · NA
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02566057 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 36 participants.
The verdict
NCT02566057, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
Interventions
- BIOLOGICAL PGx testing guided treatment (PGT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-07-10 |
| Est. Completion | 2017-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02566057
The ClinicalTrials.gov registry entry for NCT02566057 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PGx testing guided treatment (PGT) is the first listed.
NCT02566057 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02566057 about?
NCT02566057 is a clinical study titled "Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis". This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
What is the current status of trial NCT02566057?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2014-07-10. Estimated completion is 2017-12-31.
What interventions are being tested in trial NCT02566057?
The interventions under investigation include: PGx testing guided treatment (PGT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02566057?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.